News stories about Syneron Medical (NASDAQ:ELOS) have trended somewhat negative on Saturday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syneron Medical earned a media sentiment score of -0.09 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 47.476905841206 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Syneron Medical (ELOS) opened at $11.00 on Friday. Syneron Medical has a 52 week low of $6.18 and a 52 week high of $11.43.
TRADEMARK VIOLATION WARNING: “Syneron Medical (ELOS) Given Media Impact Score of -0.09” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/syneron-medical-elos-given-media-impact-score-of-0-09.html.
Syneron Medical Company Profile
Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.
Receive News & Ratings for Syneron Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical and related companies with MarketBeat.com's FREE daily email newsletter.